Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II trial of docetaxel plus carboplatin in hormone-refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy

A phase II trial of docetaxel plus carboplatin in hormone-refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Proc ASCO Prostate. 2007; (in press).


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.